Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-hour versus 12-hour linezolid administration in ICU patients with renal failure
IRCT20251202068186N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of linezolid in Gram-positive bacterial infection (2 arms), sponsored by Tehran University of Medical Sciences. Started Mar 2026; status: completed.
02
Drugs
linezolid
03
Conditions
Gram-positive bacterial infection
Beyond the preview
Go deeper on IRCT20251202068186N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251202068186N1.